NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

May 31, 2013

Conditions

Colon Cancer

Interventions

DRUG

NGR-hTNF

iv 0.8 or 45 mcg/sqm q3W

DRUG

Oxaliplatin

iv q3W 100 mg/sqm 60 minutes after NGR-hTNF infusion

DRUG

capecitabine

orally 825 mg/sqm 2qDx14

Trial Locations (1)

Azienda Ospedaliera Universitaria San Martino, Genoa